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The four serotypes of dengue virus (DENV1-4) are the causal agents of
the emerging disease Dengue Fever and its severe forms. DENV is
inoculated into human blood through a mosquito bite. Thus, plasma is
an important media for DENV dissemination in infected persons and
several important interactions should take place for the virus with
human plasma proteins that strongly inﬂuence or may determine the
course of the infection. This dataset contains 239 proteins identiﬁed in
the elution fractions of human plasma subjected to DE-52 anion
exchange chromatography. Data on DENV2 infection of Huh 7.5 cells in
presence of the human plasma fraction is also presented.
& 2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Speciﬁcations tableubject area Biology
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V. Huerta et al. / Data in Brief 6 (2016) 352–358 353ype of data Figures, table and an excel ﬁle with the output of Thermo Scientiﬁc™ Proteome
Discoverer™ softwareow data was
acquiredMass spectrometry, linear trap quadrupole (LTQ)-Orbitrap Velos mass
spectrometerata format Processed
xperimental
factorsDengue infection under different Human plasma samples preparationsxperimental
featuresHuman plasma was adjusted to pH 6.0 and subjected to anion exchange chro-
matography. Elution fractions were digested with trypsin and protein species
were identiﬁed by peptide sequencing. Virology assays were performed to
investigate the effect of plasma fractions on dengue virus infection to human
cells.ata source
locationCenter for Genetic Engineering and Biotechnology, Havana, Cubaata accessibility In this article and in supplementary ﬁleD2. Value of the data This data could be of interest to laboratories studying the interactions of DENV with human plasma
proteins.
 Data presented can be compared with list of proteins identiﬁed by different methodologies as
putative DENV binding proteins.
 Data of proteins present in the different chromatography fractions could be useful for laboratories
working on the fractionation of human plasma using different chromatographic approaches.3. Data
This dataset describes conditions of chromatographic fractionation of human plasma resulting in a
protein sample able to modulate DENV infection in mammalian cells, provides the identity of proteins
contained in the different chromatography fractions and presents data on the infection of Huh
7.5 cells with DENV2 in presence of abovementioned human plasma sample.4. Experimental design, materials and methods
4.1. Viruses and cell lines
DENV2 (strain SB8553, isolated in Malaysia in 2002) and Huh 7.5 cells were kindly donated by Dr.
Lisset Hermida (CIGB, Cuba) and Dr. Félix Rey (Pasteur Institute, France), respectively. DENV2 was
propagated in Vero cells (Vero, NIBSC code 011038), determining virus titers by plaque assays in the
same cell line [1]. Cells were grown in DMEM supplemented with penicillin (100 units/mL), strep-
tomycin (100 mg/mL) and 5% and 10% (v/v) heat-inactivated fetal bovine serum (FBS) for Vero and Huh
7.5 cells, respectively.
The mouse brain-derived virus preparation was obtained by homogenization of suckling mouse
brains infected with DENV2 (New Guinea strain) using RPMI-1640 medium. Puriﬁed ﬂavivirus-
reactive mAb 4G2 was provided by the Unit for Production of Monoclonal Antibodies (CIGB, Cuba).
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Frozen human plasma samples from healthy volunteers were obtained from expired stocks of local
blood banks, pooled and fractionated by anion exchange chromatography (AXC). Brieﬂy, 125 mL of
pooled human plasma were dialyzed against equilibration buffer (50 mM Hepes pH 6, 60 mM NaCl,
1 mM EDTA) and then centrifuged at 10,000 g for 30 min at 4 °C, diluted 3-fold in equilibration buffer
and subjected to tandem ﬁltration through Whatman 1 qualitative ﬁlter paper (Whatman, UK) and a
0.45 mm membrane. The resulting sample was loaded at a ﬂow rate of 10 cm/h onto an XK-26
chromatography column (GE Healthcare, USA) packed with 10 mL of DE-52 gel, which was next
washed with equilibration buffer until absorbance at 280 nm returned to baseline (bound protein
represented, in average, 1.2% of the initial protein contents of the sample and no more than 60% of the
total protein binding capacity estimated for DE-52 at pH 6.0). Then, the column was washed
sequentially with preparations of equilibration buffer containing increasing concentrations of NaCl
(0.3 M, 0.6 M and 1 M) at 30 cm/h, and the protein species still bound to the column afterwards were
eluted by the successive application of 0.02 M sodium acetate pH 3.0, water and 0.01 M NaOH.
Chromatography fractions were used either separately or pooled in a single sample (ELUAXC) [2]
(Fig. 1). Upon collection, a protease inhibitor cocktail consisting of 1 μg/mL leupeptin, 1 μg/mL pep-
statin A, 1 μg/mL soybean trypsin inhibitor and 1 mM PMSF was added to the eluted fractions, which
were subsequently dialyzed against 10 mM Hepes pH 7.0, 0.15 M NaCl, 1 mM CaCl2 and stored at
20 °C until used.Fig. 1. Fractionation of human plasma in DE-52 AXC. (a) Chromatographic proﬁle. FT, ﬂow through. Bound proteins were eluted
from the column with (I) 0.3 M NaCl, (II) 0.6 M NaCl, (III) 1 M NaCl, (IV) 100 mM sodium acetate pH 3.0, (V) water and (VI)
NaOH. (b) SDS-PAGE analysis of the chromatography fractions. MWM, molecular weight markers. The lane identiﬁcation tags
match those of the chromatogram.4.3. Virus-binding activity of plasma fractions
Microtiter plates were coated with 1 mg protein content of the corresponding AXC chromatography
fraction diluted in 50 mL of 0.05 M sodium carbonate/bicarbonate buffer, pH 9.6. After coating, the
plates were washed with 0.05% Tween 20 in 10 mM Hepes pH 7.0, 0.12 M NaCl, 1 mM CaCl2 (HBCa-T)
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1 h at 37 °C. Speciﬁed dilutions of mouse-derived DENV2 were added to the plates and the binding
reaction was allowed to proceed for 2 h at 37 °C. Bound virus was detected by incubation with bio-
tinylated Mab 4G2 at 5 mg/mL (1 h at 37 °C) followed by washing with HBCa-T and incubation with a
streptavidin–peroxidase conjugate (1 h at 37 °C). After washing, the plates were developed by adding
0.001% H2O2, 1 mg/mL o-phenylenediamine in 0.01 mol/L citric acid-phosphate buffer pH 5.0 for
20 min at room temperature, stopping the reactions by adding 20 mL of 2.5 M H2SO4, and reading
absorbance at 492 nm in a microplate reader (Fig. 2).4.4. Protein composition of AXC eluates
The pH of the AXC eluates was ﬁrst adjusted to 8.0 by adding 0.4 M Tris–HCl pH 8.0, 3 M urea (i.e.
0.3 M NaCl, 0.6 M NaCl, 1 M NaCl, AcO , H2O and NaOH). Disulﬁde bonds were reduced and the
resulting free thiol groups were alkylated by adding dithiothreitol to a ﬁnal concentration of 10 mM
and incubating samples at 37 °C for 2 h, and then adding acrylamide to a concentration of 25 mM and
incubating the samples for 1 h at 25 °C. The reduced/alkylated samples were diluted with water to
0.1 M Tris/HCl pH 8.0, 0.75 M urea and sequencing grade trypsin (Promega, USA) was added to an
enzyme:substrate ratio of 1:50, incubating the resulting mixture for 16 h at 37 °C. Before analysis by
LC-MS/MS, all peptide mixtures were desalted in Sep-Pak tC18 cartridges (Waters, USA), eluted in 60%
acetonitrile, 0.1% formic acid, concentrated by evaporation under vacuum and dissolved in 0.1%
formic acid.
Peptide digest mixtures were analyzed by liquid chromatography coupled to MS experiments (LC-
MS/MS), using an Ultimate 3000 RSLC nano system (Thermo Fisher Scientiﬁc, USA) connected on-line
to a linear trap quadrupole (LTQ)-Orbitrap Velos mass spectrometer (Thermo Fisher Scientiﬁc). One
microliter of each sample was injected into an Acclaim PepMap trap column (2 cm75 μm i.d., C18,
3 μm, 100 Å) (Dionex, USA) at 5 mL/min, using an aqueous solution containing 0.05% (v/v) tri-
ﬂuoroacetic acid and 1% acetonitrile. After three minutes, the trap column was connected to an
Acclaim PepMap RSLC 15 cm75 μm i.d., C18, 2 μm, 100 Å analytical column (Dionex, USA). The
peptides were eluted using a linear 2–35% gradient (solvent A: 0.1% (v/v) formic acid in HPLC-grade
water; solvent B: 0.1% (v/v) formic acid in HPLC-grade acetonitrile) at 300 nL/min over 66 min, fol-
lowed by a washing step of 7 min at 90% solvent B. MS spectra were acquired in the orbitrap analyzer
over a mass range of 300–2000 Th. Peptide fragmentation was performed with the collision induced
dissociation method at a normalized collision energy of 35%. MS/MS spectra were acquired in the
linear trap.Fig. 2. Results of the ELISA evaluating the binding of AXC fractions to DENV2. Data represent mean with range from two
independent experiments, each performed in triplicate.
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with the Mascot ver. 2.3 engine [3]. Searching limiters included propionamide cysteine as a ﬁxed
modiﬁcation as well as methionine oxidation and deamidation of glutamine and asparagine as
variable modiﬁcations, a precursor ion m/z tolerance of 10 ppm and trypsin as proteolytic enzyme,
with up to one missed cleavage. Only doubly- and triply-charged precursor ions were considered,
using an error of 0.2 Da for matching daughter ions in the MS/MS spectra. The false discovery rate
(FDR) was set to 1% for peptide and protein identiﬁcations. In the case of proteins identiﬁed from aFig. 3. Results of DENV2 infection in presence of ELUAXC preparation. (a) Schematic representation of time-of-addition
experiments. Horizontal bars represent the presence of ELUAXC preparation. In separated graphs are presented the results of
experiments where ELUAXC preparation was incubated with cells at 4 °C (b) or 37 °C (c). The roman numerals in the legends are
matched to those in (a). The amount of DENV2 in 24 h p.i supernatants was determined by a plaque formation assay in Vero
cells. Results represent the average of two independent experiments performed in duplicate. The error bars represent standard
deviations.
Fig. 4. Results of acute toxicity testing. Concentration is expressed in % for TX100 concentration and mg/mL for ELUAXC. Data
correspond to mean with range from two independent experiments, each performed in triplicate.
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reliable only if four or more consecutive C-terminal yn0 0 fragment ions were assigned to intense
signals and complementary bn ions were detected.
Data of protein identiﬁcation is presented in Supplementary ﬁle S1.4.5. DENV2 infection in presence of ELUAXC
Ninety-six well plates (Costar, 3597) were seeded with 3104 cells/well of the Huh 7.5 line and
incubated 18–24 h at 37 °C, 5% CO2 until 90% conﬂuence. The DENV2 inoculum was added at a
multiplicity of infection (m.o.i) of 0.01 and infection was allowed to proceed for 2 h. Non-internalized
virions were inactivated by a short treatment with Gly pH 3.0, the infection was allowed to proceed
for 24 h, and viral yield was evaluated in cell supernatants by plaque formation assays in Vero cells
(Fig. 3). For the assays involving a pre-incubation step at 4 °C, the monolayers were pre-chilled for
5 min on ice, the indicated dilutions of plasma sample alone or mixed with DENV2 in DMEM w/o FBS
were added, and the plates were further incubated for 90 min at 4 °C. Afterwards, the monolayers
were washed twice with DMEM 2% FBS (pre-chilled to 4 °C). The plates incubated with virus:plasma
sample mixtures were then incubated for 24 h at 37 °C.
Post-infection activity was evaluated by infecting the cells as described above and then, after washing
twice with DMEMw/o FBS, adding dilutions of the plasma samples in DMEMw/o FBS and incubating the
plates for 6 h at 37 °C, 5% CO2. Next, the monolayers were washed again and DMEM 2% FBS was added.
The supernatants were collected 24 h post infection for virus titration in a plaque assay using Vero cells.4.6. Toxicity assay
Vero cells were seeded in 96-well plates and treated with indicated dilutions of ELUAXC in DMEM,
2% FBS either for 2 h or 6 h at 37 °C, 5% CO2. At the end of the incubation, cell supernatants were
removed and 50 μL of 2 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
(Invitrogen, EE.UU) in PBS was added. Next, cells were incubated for 4 h at 37 °C, 5% CO2 before
solubilization of formazan crystals in 100 mL of Dimethylsulfoxide. Absorbance was measured at
540 nm. For calculation, cell death induced by 0.1% Triton X-100 was deﬁned as 100% (Fig. 4).Appendix A. Supplementary material
Supplementary data associated with this article can be found in the online version at http://dx.doi.
org/10.1016/j.dib.2015.12.016.
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